Unlock stock picks and a broker-level newsfeed that powers Wall Street.
XETRA - Delayed Quote EUR

PharmaSGP Holding SE (PSG.DE)

Compare
24.60
0.00
(0.00%)
As of April 3 at 5:36:17 PM GMT+2. Market Open.
Loading Chart for PSG.DE
  • Previous Close 24.60
  • Open 24.40
  • Bid 24.00 x --
  • Ask 25.00 x --
  • Day's Range 24.20 - 24.60
  • 52 Week Range 19.00 - 28.00
  • Volume 451
  • Avg. Volume 534
  • Market Cap (intraday) 294.959M
  • Beta (5Y Monthly) -0.07
  • PE Ratio (TTM) 15.67
  • EPS (TTM) 1.57
  • Earnings Date Apr 15, 2025
  • Forward Dividend & Yield 1.36 (5.53%)
  • Ex-Dividend Date Jun 27, 2024
  • 1y Target Est 38.75

PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. The company sells its products through pharmacies and wholesalers. It also exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2012 and is based in Gräfelfing, Germany.

pharmasgp.com

89

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PSG.DE

View More

Performance Overview: PSG.DE

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

PSG.DE
0.82%
DAX P (^GDAXI)
7.04%

1-Year Return

PSG.DE
18.85%
DAX P (^GDAXI)
15.80%

3-Year Return

PSG.DE
26.95%
DAX P (^GDAXI)
46.79%

5-Year Return

PSG.DE
23.12%
DAX P (^GDAXI)
123.73%

Compare To: PSG.DE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PSG.DE

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    294.96M

  • Enterprise Value

    257.80M

  • Trailing P/E

    15.67

  • Forward P/E

    10.25

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.59

  • Price/Book (mrq)

    7.98

  • Enterprise Value/Revenue

    2.26

  • Enterprise Value/EBITDA

    6.66

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.49%

  • Return on Assets (ttm)

    12.85%

  • Return on Equity (ttm)

    51.14%

  • Revenue (ttm)

    114M

  • Net Income Avi to Common (ttm)

    18.8M

  • Diluted EPS (ttm)

    1.57

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    37.77M

  • Total Debt/Equity (mrq)

    189.24%

  • Levered Free Cash Flow (ttm)

    20.73M

Research Analysis: PSG.DE

View More

Company Insights: PSG.DE

Research Reports: PSG.DE

View More

People Also Watch